Close Menu

Exact Sciences

The company saw orders for its Cologuard colorectal cancer test fall 63 percent during the first 20 days of April because of a decline in standard healthcare visits.

The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.

The company said that despite the uptick, the COVID-19 pandemic has negatively affected orders for its Cologuard colorectal cancer screening test.

The test is a real-time RT-PCR assay for the qualitative detection of SARS-CoV-2 nucleic acid in nasal, nasopharyngeal, and oropharyngeal swab specimens.

The investment bank said that Exact's Cologuard test continues to gain market share, and that its alternatives are largely invasive and inferior.

The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.

The companies have signed on to a new public-private initiative organized by Wisconsin's governor intended to increase the state's testing capacity.

The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.

The company said it will use the proceeds for general corporate purposes, such as the repayment of debt, working capital, and possible acquisitions.

The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.